How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cilostazol-probucol-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Cilostazol + Probucol group — Competitive Intelligence Brief

Cilostazol + Probucol group (Cilostazol + Probucol group) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent + Antioxidant lipid-lowering agent. Area: Cardiovascular.

marketed Antiplatelet agent + Antioxidant lipid-lowering agent Phosphodiesterase-3 (cilostazol); LDL oxidation pathway (probucol) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Cilostazol + Probucol group (Cilostazol + Probucol group) — Otsuka Beijing Research Institute. This combination drug inhibits platelet aggregation and reduces cholesterol oxidation to improve blood flow and reduce cardiovascular events.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cilostazol + Probucol group TARGET	Cilostazol + Probucol group	Otsuka Beijing Research Institute	marketed	Antiplatelet agent + Antioxidant lipid-lowering agent	Phosphodiesterase-3 (cilostazol); LDL oxidation pathway (probucol)
Cilostazol+Probucol	Cilostazol+Probucol	Otsuka Beijing Research Institute	marketed	Antiplatelet agent + Antioxidant lipid-lowering agent	Phosphodiesterase-3 (cilostazol); Antioxidant mechanism (probucol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent + Antioxidant lipid-lowering agent class)

Otsuka Beijing Research Institute · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cilostazol + Probucol group — Competitive Intelligence Brief. https://druglandscape.com/ci/cilostazol-probucol-group. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab